Testing for Epidermal Growth Factor Receptor in Lung Cancer: Have We Learned Anything From HER-2 Testing?

2004 ◽  
Vol 22 (17) ◽  
pp. 3646-3646 ◽  
Author(s):  
Hadi Yaziji ◽  
Allen M. Gown
2010 ◽  
Vol 2010 ◽  
pp. 1-6 ◽  
Author(s):  
Giuseppe De Palma ◽  
Paola Mozzoni ◽  
Olga Acampa ◽  
Eveline Internullo ◽  
Paolo Carbognani ◽  
...  

This study was aimed at: (i) investigating the expression profiles of some antioxidant and epidermal growth factor receptor genes in cancerous and unaffected tissues of patients undergoing lung resection for non-small cell lung cancer (NSCLC) (cross-sectional phase), (ii) evaluating if gene expression levels at the time of surgery may be associated to patients' survival (prospective phase). Antioxidant genes included heme oxygenase 1 (HO-1), superoxide dismutase-1 (SOD-1), and -2 (SOD-2), whereas epidermal growth factor receptor genes consisted of epidermal growth factor receptor (EGFR) and v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2 (HER-2). Twenty-eight couples of lung biopsies were obtained and gene transcripts were quantified by Real Time RT-PCR. The average follow-up of patients lasted about 60 months. In the cancerous tissues, antioxidant genes were significantly hypo-expressed than in unaffected tissues. TheHER-2transcript levels prevailed in adenocarcinomas, whereasEGFRin squamocellular carcinomas. Patients overexpressingHER-2in the cancerous tissues showed significantly lower 5-year survival than the others.


Cancer ◽  
2006 ◽  
Vol 106 (10) ◽  
pp. 2200-2207 ◽  
Author(s):  
Makoto Suzuki ◽  
Hisayuki Shigematsu ◽  
Toshihiko Iizasa ◽  
Kenzo Hiroshima ◽  
Yukio Nakatani ◽  
...  

2018 ◽  
Vol 18 (8) ◽  
pp. 773-791
Author(s):  
Dhaval Sanchala ◽  
Lokesh K. Bhatt ◽  
Kedar S. Prabhavalkar

Lung cancer surfaces to be the predominant determinant of mortality worldwide constituting 13% and 19% of all new cancer cases and deaths related to cancer respectively. Molecular profiling has now become a regular trend in lung cancer to identify the driver mutations. Epidermal Growth Factor Receptor (EGFR) is the most regular driver mutation encountered in Non-Small Cell Lung Cancer (NSCLC). Targeted therapies are now available for the treatment of EGFR mutant NSCLC. EGFR mutation is more frequently expressed in adenocarcinoma than squamous cell carcinoma. This article presents a detailed molecular insight of the therapeutic approaches for the treatment of EGFR mutant lung cancer. The article delineates molecular mechanism of the drugs that are approved, the drugs that are in clinical trial and the drugs that have not entered a clinical trial but shows promising future in the treatment of EGFR mutant lung cancer. Furthermore, this article provides concise information on relevant combinational or monotherapy clinical trials that have been completed for various approaches.


Sign in / Sign up

Export Citation Format

Share Document